ScanSource Q1 FY2027 Earnings: Revenue Growth Comes with Margin Pressure
ScanSource reported fiscal Q1 2027 net sales of $962.3 million, up 30.1% year-over-year, driven by strong hardware demand and the MicroAge acquisition. Despite top-line growth, GAAP diluted EPS fell 52.8% to $0.42. Profitability and cash flows were pressured by a lower-margin sales mix, increased operating expenses, and a $4.5 million bad debt expense primarily tied to Brazil credit exposures. Operating cash flow turned negative at $42.3 million. Management updated fiscal 2027 guidance, raising the adjusted EBITDA range to $175–$185 million while maintaining a free cash flow target of at least $85 million.
ScanSource (NASDAQ: SCSC) reported fiscal Q1 2027 net sales of $962.3 million for the quarter ended September 30, 2026, up 30.1% year over year, while GAAP diluted EPS fell to $0.42 from $0.89. Gross profit increased, but hardware-heavy demand and more lower-margin large deals compressed gross margin, while higher bad debt expense further reduced earnings. Operating and free cash flow were negative as working capital and the MicroAge acquisition increased cash requirements.
Core Financial Results
Top-line growth did not translate into comparable profit growth. Gross profit increased 8.8%, substantially less than sales, while operating income, net income and adjusted EBITDA all declined.
The following table compares the quarter with fiscal Q1 2026. Dollar amounts are in millions except per-share data.
| Metric | Q1 FY2027 | Q1 FY2026 | Year-over-Year Change |
|---|---|---|---|
| Net sales | $962.3 million | $739.7 million | +30.1% |
| Gross profit | $116.9 million | $107.5 million | +8.8% |
| Gross margin | 12.2% | 14.5% | -238 basis points |
| Operating income | $12.4 million | $25.9 million | -52.2% |
| GAAP net income | $8.7 million | $19.9 million | -56.3% |
| GAAP diluted EPS | $0.42 | $0.89 | -52.8% |
| Adjusted EBITDA | $31.3 million | $38.6 million | -18.9% |
| Adjusted EBITDA margin | 3.25% | 5.22% | -197 basis points |
| Non-GAAP diluted EPS | $0.86 | $1.06 | -18.9% |
| Operating cash flow | -$42.3 million | $23.2 million | Swung negative |
Non-GAAP results exclude items including acquisition-related amortization, acquisition and divestiture costs, restructuring costs and certain other adjustments.
Business and Segment Performance
Specialty Technology Solutions generated most of the company’s sales growth, supported by broad-based demand in North America. Its reported sales rose 28.2%, while acquisition- and currency-adjusted growth was 27.5%.
Intelisys & Solution Services posted much faster reported growth, but most of the increase came from acquisitions. Reported segment sales rose 85.9%, compared with 3.2% growth after excluding acquisition effects.
| Business Metric | Q1 FY2027 | Q1 FY2026 | Year-over-Year Change |
|---|---|---|---|
| Specialty Technology Solutions sales | $917.3 million | $715.4 million | +28.2% |
| Intelisys & Solution Services sales | $45.0 million | $24.2 million | +85.9% |
| Intelisys sales excluding acquisitions | $25.0 million | $24.2 million | +3.2% |
| Products and services sales | $919.9 million | $703.0 million | +30.8% |
| Recurring revenue | $42.4 million | $36.7 million | +15.7% |
| United States and Canada sales | $914.0 million | $682.2 million | +34.0% |
| Brazil sales | $48.3 million | $57.4 million | -15.9% |
ScanSource completed its acquisition of MicroAge on September 1, 2026, and included it in Intelisys & Solution Services. The acquisition adjustment represented $20.0 million of segment sales during the quarter. Management said MicroAge adds higher-margin capabilities in cloud, cybersecurity, data center and AI solutions.
Hardware-Led Growth Compressed Margins, and Brazil Credit Exposure Added Pressure
Products and services sales grew faster than recurring revenue, reflecting strong hardware demand and a greater mix of lower-margin large transactions. This mix caused gross margin to fall by 238 basis points even though gross profit dollars increased. Recurring revenue’s share of gross profit improved to 32.8% from 31.7%, but it was not enough to offset the broader sales-mix effect.
Selling, general and administrative expenses increased to $96.5 million from $75.3 million. Operating results also included approximately $4.5 million of additional bad debt expense, primarily related to specific customer credit exposures in Brazil. ScanSource estimated that this expense reduced diluted EPS by approximately $0.16.
These pressures help explain why operating income declined 52.2% and adjusted EBITDA fell 18.9% despite higher sales and gross profit.
Cash Flow and Balance Sheet
ScanSource used $42.3 million of operating cash and reported negative free cash flow of $44.1 million. Management attributed the cash use primarily to working capital investments supporting growth; cash flow changes included a $25.6 million inventory increase and an $8.0 million use related to accounts receivable, excluding acquisition effects.
Cash and equivalents ended the quarter at $45.9 million, down from $88.4 million at June 30, 2026. Total debt was $332.4 million, including $231.9 million of revolving credit borrowings. The quarter also included $217.8 million of net cash paid for acquisitions and $4.8 million of share repurchases.
Fiscal 2027 Guidance
ScanSource replaced its previous full-year outlook with updated guidance that includes MicroAge. The adjusted EBITDA range increased, while the free cash flow target remained unchanged.
| Metric | Latest FY2027 Guidance | Previous Guidance | Change |
|---|---|---|---|
| Net sales | $3.8 billion to $4.0 billion | 6% to 10% year-over-year growth | Replaced with an absolute range including MicroAge |
| Adjusted EBITDA | $175 million to $185 million | $158 million to $165 million | Low end raised $17 million; high end raised $20 million |
| Free cash flow | At least $85 million | At least $85 million | Unchanged |
The annual outlook covers the fiscal year ending June 30, 2027. Reaching the unchanged free cash flow target will require a substantial improvement from the first quarter’s negative result.
Recent Insider Transactions
The supplied six-month summary lists 228,307 shares purchased across 15 transactions and 95,632 shares sold across four transactions, resulting in net purchases of 132,675 shares. Total insider holdings were listed at approximately 505,380 shares.
Recent records with nonzero reported values included the following direct-ownership transactions. Reported values are in U.S. dollars.
| Insider | Role | Date | Transaction | Price per Share | Reported Value |
|---|---|---|---|---|---|
| Michael L. Baur | Chief Executive Officer | September 11, 2026 | Derivative exercise or conversion | $37.00 | $2,861,543 |
| Charles Alexander Mathis | Director | September 11, 2026 | Sale | $58.00 | $174,000 |
| Michael L. Baur | Chief Executive Officer | September 11, 2026 | Sale | $55.39–$58.14 | $4,438,747 |
| Brandy Ford | Officer | September 4, 2026 | Sale | $57.43–$58.04 | $303,998 |
| Stephen Jones | Chief Financial Officer | September 3, 2026 | Sale | $56.69–$57.21 | $567,574 |
The latest records also included zero-price stock awards to multiple directors and officers on September 1. These were compensation grants rather than open-market purchases, and the transactions alone do not establish insiders’ views on the company’s outlook.
Risks Investors Should Monitor
- Sales-mix pressure: Continued growth in hardware and lower-margin large deals could keep gross margin below the prior-year level even if revenue remains elevated.
- Brazil credit exposure: Brazil sales declined 15.9%, while customer credit issues in the country produced approximately $4.5 million of additional bad debt expense during the quarter.
- Cash conversion: Negative operating and free cash flow increased the importance of working capital management, particularly with full-year free cash flow guidance still set at a minimum of $85 million.
- Acquisition execution and leverage: MicroAge expands ScanSource’s capabilities but also increases integration requirements. The acquisition occurred alongside higher debt and lower quarter-end cash.
Summary
ScanSource’s fiscal Q1 2027 showed substantial demand growth, led by Specialty Technology Solutions and North America, while MicroAge boosted reported Intelisys sales. However, a hardware-heavy mix, lower-margin large deals and Brazil-related bad debt caused earnings and margins to decline. Investors’ next focal points are margin stabilization, improved cash conversion, resolution of credit exposure and the integration of MicroAge within the updated fiscal 2027 outlook.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.